PuSH - Publikationsserver des Helmholtz Zentrums München

Paulin, N.* ; Döring, Y.* ; Kooijman, S.* ; Blanchet, X.* ; Viola, J.R.* ; de Jong, R.* ; Mandl, M.* ; Hendrikse, J.* ; Schiener, M.* ; von Hundelshausen, P.* ; Vogt, A.* ; Weber, C.* ; Bdeir, K.* ; Hofmann, S.M. ; Rensen, P.C.N.* ; Drechsler, M.* ; Soehnlein, O.*

Human neutrophil peptide 1 Limits hypercholesterolemia-induced atherosclerosis by increasing hepatic LDL clearance.

EBioMedicine 16, 204-211 (2017)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Increases in plasma LDL-cholesterol have unequivocally been established as a causal risk factor for atherosclerosis. Hence, strategies for lowering of LDL-cholesterol may have immediate therapeutic relevance. Here we study the role of human neutrophil peptide 1 (HNP1) in a mouse model of atherosclerosis and identify its potent atheroprotective effect both upon transgenic overexpression and therapeutic delivery. The effect was found to be due to a reduction of plasma LDL-cholesterol. Mechanistically, HNP1 binds to apolipoproteins enriched in LDL. This interaction facilitates clearance of LDL particles in the liver via LDL receptor. Thus, we here identify a non-redundant mechanism by which HNP1 allows for reduction of LDL-cholesterol, a process that may be therapeutically instructed to lower cardiovascular risk.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Atherosclerosis ; Human Neutrophil Peptide ; Hypercholesterolemia ; Ldl Receptor ; Neutrophil
ISSN (print) / ISBN 2352-3964
e-ISSN 2352-3964
Zeitschrift EBioMedicine
Quellenangaben Band: 16, Heft: , Seiten: 204-211 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam [u.a.]
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Regeneration Research (IDR)